A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of CM313(SC) Injection in Subjects With Systemic Lupus Erythematosus
Latest Information Update: 30 Jan 2025
Price :
$35 *
At a glance
- Drugs CM 313 (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Sponsors KeyMed Biosciences
- 30 Jan 2025 New trial record